TCON - TRACON Pharmaceuticals Inc. Year-over-year earnings per share growth for the last twelve months

The prospects for TRACON Pharmaceuticals (TCON) depend on the outcomes for envafolimab and legal settlements, as clearly demonstrated by the quarterly EPS change. The latest parameter stands at 0.00. TRACON Pharmaceuticals (TCON) focuses on precision oncology for sarcoma therapy in specialized centers. However, a severe staffing crisis and a reduction in research personnel have significantly limited the issuer's internal development potential.
traconpharma.com (TCON) - metric breakdowns and financial figures

TRACON Pharmaceuticals revenues from licensing payments and antibody development drive profit dynamics, as reflected in the quarterly EPS growth assessment. This indicator measures the percentage change in net income per share compared to the previous period, allowing investors to distinguish genuine business efficiency growth from temporary liquidity spikes driven by the Fed's accommodative monetary policy.